MacKay Edward O, Gelatt Kirk N
Department of Small Animal Clinical Sciences and Gwathmey-Adams Laboratory for Vision Science, College of Veterinary Medicine, University of Florida, PO Box 100126, Gainesville, FL 32610-0126, USA.
Vet Ophthalmol. 2013 May;16(3):198-203. doi: 10.1111/j.1463-5224.2012.01057.x. Epub 2012 Jul 31.
To evaluate effects of Coherin™ on intraocular pressure (IOP), pupil size (PS), and heart rate (HR) in glaucomatous Beagles in single-dose studies in a pilot study.
Intraocular pressure, PS, and HR were measured in eight glaucomatous Beagles. One randomly chosen eye received single 50 μL doses of differing concentrations of Coherin™ (treated eye) or vehicle (placebo-treated eye), and the fellow eye served as the untreated control. After the first measurements, a single dose of either Coherin™ or sterile water vehicle was instilled in the drug and placebo eyes, respectively.
The mean ± SEM diurnal changes in IOP after 0.005%, 0.01%, 0.2%, 0.284%, 1%, 2%, and 4% topical Coherin™ once daily were 7.6 ± 3.2 mmHg, 15.5 ± 5.3 mmHg, 11.2 ± 4.4 mmHg, 11.8 ± 4.4 mmHg, 19.1 ± 3.8 mmHg, 5.0 ± 1.8 mmHg, and 8.8 ± 2.8 mmHg, respectively. The declines in IOP were significantly different (P < 0.05) from the untreated control eyes with the 0.2% and 0.284% Coherin™-treated eyes and suggestive for 1% Coherin™ concentrations. No signs of irritation, significant PS, and HR changes were detected in the Coherin™-treated eyes.
Of seven different concentrations, 2% and 0.248% Coherin™ produced significant declines in IOP in the glaucomatous beagle in single-dose studies when compared to both untreated control and placebo-treated eyes. One percent Coherin™ solution produced significant IOP decreases compared with the placebo-treated eye but not the untreated control eyes. No local ocular irritation, PS and HR changes were observed in Coherin™-treated eyes. This pilot study suggests that topical Coherin™ has potential as an ocular hypotensive agent.
在一项初步研究的单剂量研究中，评估Coherin™对青光眼比格犬眼压（IOP）、瞳孔大小（PS）和心率（HR）的影响。
对8只青光眼比格犬测量眼压、PS和HR。随机选择一只眼睛接受不同浓度Coherin™的单次50 μL剂量（治疗眼）或赋形剂（安慰剂治疗眼），另一只眼睛作为未治疗对照。首次测量后，分别向用药眼和安慰剂眼滴入单次剂量的Coherin™或无菌水赋形剂。
每天一次局部使用0.005%、0.01%、0.2%、0.284%、1%、2%和4%的Coherin™后，IOP的平均±标准误昼夜变化分别为7.6±3.2 mmHg、15.5±5.3 mmHg、11.2±4.4 mmHg、11.8±4.4 mmHg、19.1±3.8 mmHg、5.0±1.8 mmHg和8.8±2.8 mmHg。使用0.2%和0.284%的Coherin™治疗的眼睛，其眼压下降与未治疗的对照眼睛有显著差异（P<0.05），1%浓度的Coherin™也有此趋势。在Coherin™治疗的眼睛中未检测到刺激迹象、明显的PS和HR变化。
在单剂量研究中，与未治疗对照和安慰剂治疗的眼睛相比时，七种不同浓度的Coherin™中有2%和0.248%使青光眼比格犬的IOP显著下降。与安慰剂治疗的眼睛相比，1%的Coherin™溶液使IOP显著降低，但与未治疗对照眼睛相比则不然。在Coherin™治疗的眼睛中未观察到局部眼部刺激、PS和HR变化。这项初步研究表明局部使用Coherin™有作为降眼压药物的潜力。
